Abstract
Immunotherapy of cancer could be possible in cases in which competent effector T cells can be induced. Such an approach depends on expression of tumour-specific antigens by the tumour cells and on the availability of sufficient costimulatory support for activation of cytotoxic T lymphocytes. Here, a strategy for helper T cell recruitment for induction of tumour-specific cytotoxic immune responses is presented. Allogenic MHC class II molecules were introduced into tumour cells by cell fusion. These hybrid cells, when injected into mice, induced rejection of an established tumour. The contribution of CD4-expressing helper T cells in the induction phase and of CD8-expressing T cells in the effector phase of the immune response was demonstrated. The approach described could be applicable to cases in which a suitable tumour antigen is present but not identified; it employs regulatory interactions that govern physiological immune responses and is designed to be minimally invasive.
Key words: Tumour rejection, CTL, Helper cells
References
- 1.Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 1971;7:3. doi: 10.1111/j.1600-065x.1971.tb00461.x. [DOI] [PubMed] [Google Scholar]
- 2.Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res. 1992;58:177. doi: 10.1016/s0065-230x(08)60295-x. [DOI] [PubMed] [Google Scholar]
- 3.Franksson L, Petersson M, Kiessling R, Kärre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol. 1993;23:2606. doi: 10.1002/eji.1830231034. [DOI] [PubMed] [Google Scholar]
- 4.Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 1992;58:143. doi: 10.1016/s0065-230x(08)60294-8. [DOI] [PubMed] [Google Scholar]
- 5.Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. J Immunol. 1993;151:4209. [PubMed] [Google Scholar]
- 6.Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL. Human cytotoxic T-cell lines with restricted specificity for Squamous-cell carcinoma of the head and neck. Cancer Res. 1993;53:1461. [PubMed] [Google Scholar]
- 7.Ioannides CG, Whiteside TL. T-cell recognition of human tumors — implications for molecular immunotherapy of cancer. Clin Immunol Immunpathol. 1993;66:91. doi: 10.1006/clin.1993.1012. [DOI] [PubMed] [Google Scholar]
- 8.Maas RA, Dullens HFJ, DenOtter W. Interleukin-2 in cancer treatment — disappointing or (still) promising. Cancer Immunol Immunother. 1993;36:141. doi: 10.1007/BF01741084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Colombo MP, Mattei S, Parmiani G. Cytokine gene transfer in tumor cells as an approach to antitumor therapy. Int J Lab Res. 1992;21:278. doi: 10.1007/BF02591661. [DOI] [PubMed] [Google Scholar]
- 10.Hock H, Dorsch M, Kunzendorf U, Qin ZH, Diamantenstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-γ. Proc. Natl Acad Sci USA. 1993;90:2774. doi: 10.1073/pnas.90.7.2774. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen LP, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, Mcgowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the lymphocyte-T molecule CD28 and CTLA4. Cell. 1992;71:1093. doi: 10.1016/s0092-8674(05)80059-5. [DOI] [PubMed] [Google Scholar]
- 12.Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368. doi: 10.1126/science.7678351. [DOI] [PubMed] [Google Scholar]
- 13.Stuhler G, Walden P. Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol. 1993;23:2279. doi: 10.1002/eji.1830230934. [DOI] [PubMed] [Google Scholar]
- 14.Gorer PA. Studies in antibody response of mice to tumour inoculation. Br J Cancer. 1950;4:372. doi: 10.1038/bjc.1950.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675. doi: 10.1038/319675a0. [DOI] [PubMed] [Google Scholar]
- 16.Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549. [PubMed] [Google Scholar]
- 17.Chang DC, Chassy BM, Saunders JA, Sower AE, editors. Guide to electroporation and electrofusion. San Diego: Academic Press; 1992. [Google Scholar]
- 18.Fischer AG, Goff LK, Lightstone L, Marvel J, Mitchison NA, Poirier G, Stauss H, Zamoyska R. Problems in the physiology of class I and class II MHC molecules, and of CD45. CSH Symp Quant Biol. 1989;54:667. doi: 10.1101/sqb.1989.054.01.078. [DOI] [PubMed] [Google Scholar]
- 19.Guo Y, Wu M, Chen H, Wang X, Liu G, Lu G, Ma J, Sy M-S. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 1994;263:518. doi: 10.1126/science.7507262. [DOI] [PubMed] [Google Scholar]